Buy Propecia (Finasteride) online and save money! Worldwide delivery, no prescription!
The longest running hair loss treatment clinical trial in history is showing continued effectiveness in Propecia after 5 full years of use. New Five-Year Study with Propecia Showed That the `Hair Count' Gap Grew Over Time Between Men Who Treated Hair Loss with Propecia, Compared to Men Who Didn't use this drug at all.
The longest controlled clinical trial of a hair loss treatment ever reported showed that men who took Propecia compared to men who took a placebo had a big difference in their hair counts after five years, according to data presented at the 59th Annual Meeting of the American Academy of Dermatology.
The new study reported a difference of 277 hairs in a one-inch diameter circle of scalp in favor of men treated with Propecia for five years (n=219) vs. those who did received a placebo (n=15). Baseline hair counts of all men at the initial stage of the study averaged 876 hairs in the one-inch diameter circle.
"This study provides new, long-term scientific data that Propecia helped the majority of men with predominantly vertex male pattern hair loss keep the amount of hair they possess," said Keith Kaufman, M.D., senior director of Merck Research Laboratories. "The study also was the first controlled clinical trial to assess the course of untreated hair loss over a five-year period and to show the progressive nature of male pattern hair loss."
Made by Merck & Co., Inc., Propecia is used for the treatment of certain types of hair loss in men only, based upon two-year studies. Propecia is a single dose a day treatment and is the only pill for male pattern hair loss approved by the Food and Drug Administration. Hair loss affects nearly approximately 30 million men in the United States. Propecia is not recommended for use in women or children.
The five-year data are from investigational extension studies of double- blind placebo-controlled clinical trials that first showed the safety and efficacy of Propecia in 1,553 men age 18 to 41 with mild-to-moderate male pattern hair loss (androgenetic alopecia) in the vertex region (top of the head). Efficacy in bi-temporal recession has not been established by using this drug.